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Background: Efficacy of thrombectomy treatment in acute ischemic stroke
large vessel occlusion (AIS-LVO) patients is time dependent. Direct admission
to thrombectomy centers (vs. interhospital transfer) may reduce time to
treatment and improve outcomes. In this subset analysis of the COMPLETE
registry, we compared outcomes between direct to thrombectomy center
(Direct) vs. transfer from another hospital to thrombectomy center (Transfer)
in AIS-LVO patients treated with aspiration thrombectomy.
Methods: COMPLETE was a prospective, international registry that enrolled
patients from July 2018 to October 2019, with a 90-day follow-up period
that was completed in January 2020. Imaging ﬁndings and safety events were
adjudicated by core lab and independent medical reviewers, respectively.
Pre-deﬁned primary endpoints included post-procedure angiographic
revascularization (mTICI ≥2b), 90-day functional outcome (mRS 0–2), and
90-day all-cause mortality. Planned collections of procedural time metrics and
outcomes were used in the present post-hoc analysis to compare outcomes
between transfer and direct patient cohorts.
Results: Of 650 patients enrolled, 343 were transfer [52.8% female;
mean (SD) age, 68.2 (13.9) years], and 307 were direct [55.4% female;
68.5 (14.5) years] admit. Median onset-to-puncture time took longer
in the transfer vs. direct cohort (5.65 vs. 3.18 h: 2.33 h difference,
respectively; p < 0.001). There was no signiﬁcant difference in successful
revascularization rate, mTICI ≥2b (88.3 and 87.3%), sICH at 24 h (3.8
and 3.9%), median length of hospital stay (7 and 6 days), and 90-day
mortality (16.9 and 14.0%) between transfer vs. direct patients, respectively.
However, achieving 90-day functional independence was less likely in transfer
compared with direct patients (mRS 0–2 was 50.3 vs. 61.7%, p = 0.0056).
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Conclusions: In the COMPLETE registry, direct to thrombectomy center was
associated with signiﬁcantly shorter onset-to-puncture times, and higher rates
of good clinical outcome across different geographies. Additional research
should focus on AIS-LVO detection to facilitate direct routing of patients to
appropriate treatment centers.
Clinical
trial
registration:
identiﬁer: NCT03464565).

https://clinicaltrials.gov
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Introduction

delayed by an average of 12.0 min, endovascular treatment
would be delivered 91.0 min sooner, had patients been directly
routed to endovascular-capable centers (7).
By contrast, RACECAT, a randomized controlled trial
conducted in Catalonia region of Spain, reported that both direct
and transfer pre-hospital protocols yielded similar 90-day mRS
outcomes in both patient cohorts (8).
Many U.S. and European geographies however, lack unified
stroke transfer protocols, and patient transport is subject to
regional emergency medical services or triage policy (9, 10).
This variability contrasts with the pre-hospital triage efficiency
of RACECAT, which was run within a well-integrated public
health network (8).
In this subset analysis, we analyzed outcomes from patients
enrolled in the COMPLETE registry who were either directly
admitted, or secondarily transferred, to a thrombectomy capable
center. This trial included 42 sites from North America (29) and
Europe (13), comprising six countries, 12 European cities, and
17 U.S. states across major metropolitan and rural catchments
(1, 11, 12).
This study was designed to assess systems of care across
different geographies, and included both anterior and posterior
LVO patients with no restrictions on stroke onset time.

Endovascular mechanical thrombectomy (MT) represents
the current standard of care for acute ischemic stroke secondary
to large vessel occlusion (AIS-LVO) (1, 2).
Treatment outcomes for thrombolysis and thrombectomy
are time sensitive (1). A recent meta-analysis showed that the
benefits of endovascular thrombectomy are most pronounced
in patients treated within 2 h of symptom onset, with
each additional 1-h delay associated with lower functional
independence (mRS 0–2) (3).
Current systems of care for patients with suspected LVO
involve pre-hospital triage which routes patients either directly
to a stroke center capable of mechanical thrombectomy, or
initially to a nearer hospital without endovascular capability,
but which may still offer intravenous tissue plasminogen
activator (IV-tPA). It is therefore important to understand
whether centers offering only IV-tPA should be bypassed for
direct admission to comprehensive stroke centers offering
mechanical thrombectomy.
In many circumstances, direct admission to thrombectomy
centers (as compared with interhospital transfer) may
improve clinical and functional outcomes (4–6). In STRATIS,
a prospective registry, patients directly admitted to an
endovascular-capable center had significantly reduced treatment
delays and a better chance of achieving functional independence,
as compared to transfer patients (7). Furthermore, IV-tPA did
not significantly affect outcomes in this cohort. Hypothetical
bypass modeling suggested that although IV-tPA would be

Materials and methods
Study design and participants
COMPLETE was a global, prospective, multicenter, singlearm, observational registry assessing the performance and safety
of the Penumbra System in a patient population with AISLVO (ClinicalTrials.gov Identifier: NCT03464565). The data
supporting the findings of this study are available from the
corresponding author upon reasonable request.
Inclusion criteria were: (1) patient age ≥18 years, (2) prestroke mRS 0–1, (3) Patient experiencing AIS secondary to
intracranial LVO who are eligible for MT using the Penumbra

Abbreviations: AIS, acute ischemic stroke; ASPECTS, Alberta stroke
program early CT score; ECASS, European cooperative acute stroke
study; ENT, embolization in previously uninvolved or new territories; IV,
intravenous; LVO, large vessel occlusion; mRS, modiﬁed Rankin Score;
mTICI, modiﬁed thrombolysis in cerebral infarction; MT, mechanical
thrombectomy; NIHSS, National Institutes of Health stroke scale; SAE,
serious adverse event; sICH, symptomatic intracranial hemorrhage; tPA,
tissue plasminogen activator.
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Study committees

System, (4) Planned frontline treatment with Penumbra System,
and (5) Signed informed consent per Institution Review
Board/Ethics Committee.
Exclusion criteria were: (1) Any comorbid disease or
condition expected to compromise survival or ability to
complete follow-up assessments through 90 days, and (2)
Currently participating in an investigational (drug, device, etc.)
clinical trial that will confound registry endpoints. Patients in
observational, natural history, and/or epidemiological studies
not involving intervention are eligible.
Participating hospitals maintained a screening and
enrollment log of all AIS-LVO patients admitted into the
hospital who were eligible for MT. Reason(s) for exclusion were
recorded. Patients were considered enrolled once informed
consent was obtained per Institutional Review Board/Ethics
Committee and Penumbra System had been inserted into
the body. Additional details on the COMPLETE Registry are
reported separately (13).
Patients were either admitted directly to an enrolling
hospital (direct) or transferred from an outside facility to the
enrolling hospital (transfer). The decision for direct or transfer
admission to a thrombectomy center was made by the stroke
response procedures followed by the emergency services for
each enrolling hospital and not dictated by the COMPLETE
registry’s protocol.
The choice of frontline treatment using direct aspiration
only or aspiration combined with a 3D Revascularization Device
was made by the treating physician. All procedures were
conducted in accordance with routine care at each participating
hospital and the Instructions for Use for each device.
Available devices included: the Penumbra MAX, ACE, and JET
Reperfusion Catheters; the 3D Revascularization Device; and the
Penumbra Pump MAX, and ENGINE aspiration sources.

An independent imaging core lab reviewed pseudonymized
angiography for mTICI scores by pass, embolization of
new territory, pre-procedure CT for ASPECTS, CTA
for clot location, and 24-h CT to assess hemorrhagic
transformation using European Cooperative Acute Stroke
Study (ECASS) classification.
Independent medical reviewers (IMRs) reviewed and
adjudicated study endpoint events, including device related
SAEs, neurovascular procedure related SAEs, sICH within 24 h,
neurological deterioration events, and any deaths that occurred
throughout the registry. Neurological deterioration was defined
as a ≥4 point worsening of the National Institutes of Health
stroke scale (NIHSS) score from baseline and sICH was defined
as 24-h evidence of an ECASS defined ICH associated with a ≥4
point worsening of the NIHSS score from baseline.

Statistical analysis
Data was summarized using descriptive statistics. This
included the number of observations, mean, standard deviation,
median, and interquartile range (IQR) for continuous variables,
and counts and percentages for discrete variables. Comparisons
between direct and transfer patient groups were conducted using
the t-test or Wilcoxon Rank-Sum Test for continuous variables
and Fisher’s Exact Test for categorical variables. All confidence
intervals presented are Clopper-Pearson two-sided intervals. All
statistical tests were performed using SAS version 9.4 (SAS
Institute, Cary, NC) with α = 0.05.
Multivariable logistic regression models with an interaction
term for onset-to-puncture time by cohort, were used to
examine the variables associated with 90-day mRS. Candidate
clinical predictors included cohort (direct vs. transfer), onset-topuncture time (by 30 min intervals), age (by 10 year intervals),
revascularization success (TICI2b-3 post-procedure), occlusion
location, tPA (administered vs. not), baseline NIHSS (by 5 point
intervals), hypertension (present vs. not), geographic region
(US vs. Europe), baseline ASPECTS (<8 vs. ≥8). This model
included 250 patients (direct n = 129, transfer n = 121)
with witnessed stroke events and successful revascularization.
Patients with onset-to-puncture times >600 min were statistical
outliers and excluded.

Registry outcomes
The primary efficacy endpoints were: angiographic
revascularization of the occluded target vessel at immediate
post-procedure as defined by a modified thrombolysis in
cerebral infarction (mTICI) score of 2b or higher, and, good
functional subject outcome at 90 days post-procedure as defined
by a modified Rankin Score (mRS) 0–2. The primary safety
endpoint was all-cause mortality at 90 days.
Secondary endpoints included: Incidence of device- and
procedure-related Serious Adverse Events (SAEs) at ≤24 h,
occurrence of embolization in previously uninvolved or new
territories (ENT) as seen on the final control angiogram at
the end of procedure, occurrence of symptomatic intracranial
hemorrhages (sICH) at 24 h, vessel perforation, vessel dissection,
length of hospital stay, and time metrics including onset to
puncture, door to puncture and puncture to revascularization
median times.

Frontiers in Neurology

Results
From July 2018 to October 2019, the COMPLETE registry
screened 1,501 patients and enrolled 650 patients across 42 sites,
with 90 days follow up completed in January 2020. Of the 851
screen failures not enrolled in the registry, 58 met entry criteria
but declined to participate, 539 did not meet eligibility entry
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faster onset-to-puncture times (Table 4). For onset-to-puncture
time, the odds of patients achieving good functional outcome
decreased by 0.85 for every 30 min that treatment was delayed (p
= 0.0180; Table 4). No interaction effect was observed between
the direct admit cohort and onset-to-puncture time (p = 0.6612;
Figure 3). The effect of direct admission on rates of mRS 0–2 did
not persist after controlling for time from onset to puncture, nor
other baseline and procedural covariates. For patients who were
directly admitted, the odds of good functional outcome were
higher [adjusted OR 2.17 (95% CI: 0.42, 11.3)] than for transfer
patients; however, this effect was not significant (p = 0.3584).

criteria, 78 met entry criteria and consented but did not have any
component of the study devices introduced into the body, and
176 were not enrolled for other reasons. The main reasons for
exclusion were mRS >1 and planned frontline treatment with
non-Penumbra System devices. Study completion rate through
the final follow-up assessment was high (94.6%, 615/650), with
an attrition rate of 5.4% (35/650). Of the 35 patients that did not
complete the study, five withdrew consent, two were withdrawn
by a study investigator, 25 were lost to follow-up, and three did
not complete for other reasons.
Of 650 enrolled patients, 307 were treated directly at
an endovascular-capable hospital and 343 were transferred
(Table 1). Baseline characteristics were similar between the
direct and transfer patient cohorts, except for hypertension,
which was more prevalent in the transfer cohort (p < 0.01),
and median ASPECTS, which was lower in the transfer cohort
(p < 0.001; Table 1). Furthermore, the proportion of patients
with direct admissions was lower in the US (42.1%) than in
Europe (42.1% vs. 59.2%, p < 0.001).

Discussion
In the COMPLETE Study, functional independence was
improved for AIS-LVO patients directly admitted to an
endovascular-capable center, compared with those who were
transferred (90-day mRS 0–2: 61.7 vs. 50.3%; Table 3).
Furthermore, patients directly admitted to comprehensive
stroke centers had faster onset-to-puncture times (191.0 vs.
339.0 min; Table 2), which is acknowledged as a predictor of
better clinical outcomes in the American Heart and American
Stroke Association guidelines (1).

Procedural characteristics
Patients treated directly at a comprehensive stroke center
had shorter onset-to-admission times (86.5 vs. 270.0 min),
onset-to-puncture times (191.0 vs. 339.0 min), and onset to
mTICI 2b-3 else final angiogram times (242.0 vs. 373.0 min)
as compared with patients transferred secondarily (p < 0.0001
for all comparisons; Table 2; Figure 1). There was no significant
difference in procedure time (puncture to mTICI 2b-3) between
direct and transfer cohorts (Table 2); however, admission-topuncture times were longer in the direct cohort, compared to
transfer patients (p < 0.0001).

Effect of direct vs. transfer on good
functional outcome
Results from COMPLETE show that direct admission
can significantly benefit functional outcome in AIS-LVO
patients treated with frontline aspiration thrombectomy, and
mirror two similar prospective registries in which mechanical
thrombectomy was performed using stent retrievers (7), or a
combination of stent-retriever or contact aspiration firstline (6).
The magnitude of this effect was consistent across studies, with
∼10% more patients achieving mRS 0–2 at 90 days in the direct
vs. transfer cohorts: COMPLETE 61.7 and 50.3%, respectively;
STRATIS 60.0 and 52.2% (7); and, ETIS 60.1 and 52.6% (6).
To further understand the benefit of direct admission on
good functional outcome (mRS 0–2), a multivariable logistic
regression was used to adjust for baseline and procedural
characteristics (Table 4). In this analysis, the effect of direct
admission was non-significant (p = 0.3584), suggesting that
the benefits of direct admission occur indirectly, either from
variation in tPA administration, baseline NIHSS and ASPECTS,
occlusion location, or, based on predictive modeling presented
in this study, from the time interval between stroke onset
to puncture (Table 4). Furthermore, no significant interaction
effect was found between patient cohort and onset-to-puncture
time, supporting results that the benefits of direct admission can
be attributed to delays in patient treatment (Table 4).

Outcomes
Out of 650 enrolled subjects, 613 had a 90-day follow-up
assessment. Functional independence at 90 days (mRS 0–2) was
significantly higher in the direct vs. transfer group [61.7% vs.
50.3% (+11.4%); p = 0.0056; Table 3; Figure 2]. There were
no significant differences in post-procedural revascularization
rates, nor in all-cause mortality at 90 days between direct and
transfer cohorts.
Direct and transfer cohorts did not differ in rates of deviceor procedure- related SAE within 24 h, nor in rates of procedural
ENT, vessel dissection, or vessel perforation, and 24 h sICH
(Table 3). The length of hospital stay was also similar between
direct and transfer patients (6.0 vs. 7.0 days).
In the multivariable analysis, independent predictors of good
functional outcome (mRS 0–2) included lower baseline NIHSS,
baseline ASPECTS ≥8, IV-tPA administration, lower age, a
distal occlusion location (e.g. M2–M4, instead of M1), and

Frontiers in Neurology

04

frontiersin.org

Hassan et al.

10.3389/fneur.2022.896165

TABLE 1 Baseline characteristics.

Baseline characteristics

Direct (N = 307)

Transferred (N = 343)

p-Value

Age, mean (SD)

68.5 (14.5)

68.2 (13.9)

0.7808

Female, % (n/N)

55.4% (170/307)

52.8% (181/343)

0.5288

54.7% (168/307)

49.6% (170/343)

0.2084

9.1% (28/307)

10.8% (37/343)

0.5144

36.2% (111/307)

39.1% (134/343)

0.4662

US

62.2% (191/307)

76.7% (262/343)

<0.0001

EU

37.8% (116/307)

23.3% (80/343)

<0.0001

14.0% (43/307)

15.7% (54/343)

0.5820

0.3% (1/307)

0.3% (1/343)

1.0000

Cardiovascular disease

51.8% (159/307)

49.9% (171/343)

0.6379

Diabetes

23.5% (72/307)

23.9% (82/343)

0.9265

Renal failure

6.8% (21/307)

4.4% (15/343)

0.1748

Hypertension

67.1% (206/307)

76.4% (262/343)

0.0088

Hyperlipidemia

41.4% (127/307)

43.1% (148/343)

0.6910

IV tPA given, % (n/N)

47.6% (146/307)

50.7% (174/343)

0.4328

NIHSS, median [IQR]

14.0 [9.0, 20.0]

15.0 [9.0, 20.0]

0.7183

ASPECTS, median [IQR]a

8.0 [7.0, 10.0]

8.0 [7.0, 9.0]

<0.0001

pc-ASPECTS, median [IQR]b

9.0 [8.0, 10.0]

9.0 [8.0, 10.0]

0.9579

Symptom onset determination, % (n/N)
Witnessed
Wake up stroke
Unwitnessed: time last seen well
Geographic location, % (n/N)

Medical history, % (n/N)
Ischemic stroke
Hemorrhagic stroke

Occlusion location, % (n/N)
ICA

4.2% (13/307)

5.0% (17/343)

0.7111

ICA-T

12.4% (38/307)

13.1% (45/343)

0.8145

M1

55.0% (169/307)

55.4% (190/343)

0.9372

M2

18.6% (57/307)

16.3% (56/343)

0.4694

M3–M4

1.6% (5/307)

1.5% (5/343)

1.0000

A1–A2

1.0% (3/307)

0.3% (1/343)

0.3484

Basilar

4.9% (15/307)

5.2% (18/343)

0.8600

Vertebral

0.3% (1/307)

0.0% (0/343)

0.4723

PCA

2.0% (6/307)

2.9% (10/343)

0.4602

aN

direct
bN
direct

= 283, N transfer = 314.
= 22, N transfer = 27.

Effect of direct vs. transfer on the
admission-to-puncture interval

can account for the improved clinical outcomes observed in
direct admission patients.

In the COMPLETE Study, the admission-to-puncture
interval actually took significantly longer in the direct admission
patients (87 min) compared with the transfer patients (48 min;
p < 0.001; Table 3). In the ARTESp study (14), mechanical
thrombectomy was initiated significantly faster for transfer
patients following arrival at an endovascular-capable center,
due to the availability of imaging. Although this did not
compensate for the lost time incurred by secondary transport
(direct admission was twice as likely to yield a favorable clinical
outcome), this is consistent with the admission-to-puncture data
from COMPLETE and the recognition that multiple variables

Frontiers in Neurology

Effect of direct vs. transfer on technical
efficacy and safety outcomes
Revascularization success (mTICI 2b-3), 90-day mortality,
and rates of sICH, did not differ between direct vs. transfer
cohorts in the COMPLETE registry. These results are
again consistent with recent studies reporting similar
revascularization and safety outcomes regardless of patient
transfer status (6, 7).
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TABLE 2 Procedural characteristics.

Procedural characteristics

Direct (N = 307)

Transferred (N = 343)

p-Value

First line treatment
Direct aspiration

65.8% (202/307)

60.3% (207/343)

0.1669

Penumbra catheter with 3D

32.2% (99/307)

37.9% (130/343)

0.1394

Onset-to-Hospital Admission (min)

86.5 [45.0, 241.0]

270.0 [180.0, 474.0]

<0.0001

Admission-to-puncture (min)

87.0 [66.0, 115.0]

48.0 [32.0, 79.5]

<0.0001

191.0 [138.0, 388.0]

339.0 [248.0, 547.0]

<0.0001

Time metrics, median [IQR]

Onset-to-puncture (min)
Puncture-to-mTICI 2b-3 (min)
Onset-to-mTICI 2b-3 else final angiogram (min)

27.0 [15.0, 41.0]

25.0 [16.0, 40.0]

0.6937

242.0 [163.0, 433.0]

373.0 [269.0, 586.0]

<0.0001

FIGURE 1

Process times from stroke onset to revascularization (mTICI 2b-3) for direct (upper) and transfer patients (lower). Data presented as medians.
mTICI, modiﬁed thrombolysis in cerebral infarction; *p < 0.0001 for overall onset to revascularization. Stroke-onset-to-admission, p < 0.0001;
admission-to-puncture, p < 0.0001; puncture-to-revascularization, not signiﬁcant.

longer onset-to-hospital admission times, longer onset-topuncture times, and longer onset-to-revascularization times.
When comparing the symptom onset-to-revascularization
intervals between the direct (242.0 min) and transfer (373.0 min)
cohorts, patients experienced a delay of 131 min if they were
secondarily transported to an endovascular-capable center
(Table 2).
This time delay is not surprising and compares to a median
onset-to-revascularization delay in transfer patients of 109 min
(311.5 vs. 202.0 min) in STRATIS (7), and of 100 min (219.0
vs. 319.0 min) for transferred patients in ETIS (6). When
controlling for time from onset-to-treatment, the authors in
STRATIS found no difference in outcome between direct and
transfer patients, indicating for that registry population, that
improved functional outcome was attributed solely to time

Our results are further supported by recent meta-analyses
reporting no significant differences found between the two
transportation paradigms in the rate of sICH, mortality at 3
months, or in successful recanalization (15, 16).
For AIS-LVO patients eligible for mechanical
thrombectomy, treatment delays can result in unfavorable
clinical outcomes (17). Therefore, triage routing should focus
on improving interval times and reducing time imaging and
revascularization (18). For example, the interval between
symptom onset and reperfusion might be reduced by bringing
transfer patients directly to the angiosuite, a possibility
supported by data showing intrahospital processing times were
nearly twice as quick for transferred patients. Nevertheless,
in the COMPLETE registry, patients who were secondarily
transferred to an endovascular-capable center experienced

Frontiers in Neurology
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TABLE 3 Endpoints.

Endpoints

Direct (N = 307)

Transferred (N = 343)

p-Value

mTICI 2b-3 post-procedure

87.3% (268/307)

88.3% (303/343)

0.7192

mRS 0–2 at 90 days

61.7% (182/295)

50.3% (160/318)

0.0056

All-cause mortality at 90 days

14.0% (43/307)

16.9% (58/343)

0.3302

Secondary safety endpoints, % (n/N) (95% CI)
Device related SAE ≤24 h

0.3% (1/307)

0.9% (3/343)

0.6262

Procedure related SAE ≤24 h

5.5% (17/307)

6.1% (21/343)

0.8673

Embolization in previously uninvolved or new territories (ENT)

2.9% (9/307)

2.6% (9/343)

0.8162

Symptomatic intracranial hemorrhage (sICH) ≤24 h

3.9% (12/307)

3.8% (13/343)

1.0000

Vessel dissection

1.0% (3/307)

0.9% (3/343)

1.0000

Vessel perforation

0.7% (2/307)

0.0% (0/343)

0.2227

Length of hospital stay in days, median [IQR]

6.0 [3.0, 11.0]

7.0 [4.0, 11.0]

0.1091

FIGURE 2

90-day functional outcomes as measured by mRS for direct (upper, n = 295) vs. transfer (lower, n = 318) patients. Data presented as a
percentage of direct admissions vs. interhospital transfer patients. mRS, modiﬁed Rankin Scale; *p < 0.0056 for mRS 0–2 direct (61.7%) vs.
transfer (50.3%).

selective nature of the patient population for penumbral
mismatch and likely over-representation of candidates with
favorable collaterals (19, 20), emphasizing the need for nuanced,
controlled studies of transportation paradigms for AIS-LVO.

delays associated with the transfer paradigm (7). Results from
the COMPLETE registry corroborate this analysis, with direct
admissions significantly associated with both faster onset-torevascularization times, as well as better functional outcomes.
The results observed in COMPLETE are notable in that the
overall effect on functional outcome remained comparable to
registries in which transfer patients were treated approximately 1
to 2.5 h earlier than those in COMPLETE (6, 7). In COMPLETE,
time from onset-to-treatment for the highest quartile was
just over 9 h (547.0 min; Table 2); despite this, a significant
benefit was still observed between direct and transfer cohorts.
By contrast, controlled trials for late-presenting strokes (19,
20) reported equivalent benefits for both direct admissions
and for transfer patients. Nevertheless, the authors note the
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Effects of tPA on direct and transfer
IV-tPA administration was an independent predictor of
better functional outcomes for patients overall (Table 4),
although there was no significant difference in IV-tPA
administration across direct and transfer patients (Table 1).
Froehler et al. (7) remarks that although the ability to
begin IV-tPA sooner is often cited as a reason to bring
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TABLE 4 Unadjusted and adjusted logistic regression modeling for odds of achieving good functional outcome (mRS 0–2 at 90 days).

Variables

Unadjusted

Adjusted

Odds ratio (95% CI)

p-Value

Odds ratio (95% CI)

p-Value

Cohort (Direct)

1.59 (1.15, 2.19)

0.0047

2.17 (0.42, 11.3)

0.3584

tPA (Yes)

1.46 (1.06, 2.02)

0.0202

2.10 (1.05, 4.20)

0.0364

NIHSS (per 5 pts)

0.63 (0.55, 0.71)

<0.0001

0.49 (0.37, 0.64)

<0.0001

ASPECTS (≥ 8)

2.28 (1.61, 3.23)

<0.0001

2.07 (1.03, 4.15)

0.0399

Hypertension (Yes)

0.58 (0.40, 0.83)

0.0031

1.37 (0.63, 2.97)

0.4327

Region (EU)

1.04 (0.74, 1.46)

0.8332

1.19 (0.61, 2.34)

0.6070

Time: Onset-To-Puncture (per 30 mins increase)

0.98 (0.97, 1.00)

0.0365

0.85 (0.74, 0.97)

0.0180

Interaction: Onset-To-Puncture vs. Cohort

1.00 (1.00, 1.00)

0.8173

1.00 (0.99, 1.01)

0.6612

Age (per 10 yr increase)

0.66 (0.58, 0.75)

<0.0001

0.44 (0.33, 0.60)

<0.0001

TVL: (ACA) vs. M1 ref.

0.80 (0.11, 5.72)

0.8214

0.21 (0.01, 4.82)

0.3283

TVL: (ICA) vs. M1 ref.

0.62 (0.40, 0.96)

0.0341

0.99 (0.44, 2.21)

0.9755

TVL: (M2-M4) vs. M1 ref.

1.84 (1.18, 2.87)

0.0076

2.83 (1.12, 7.13)

0.0275

ACA, anterior cerebral artery; ASPECTS, Alberta stroke program early CT score; CI, confidence interval; EU, European union; ICA, internal carotid artery; M1 initial segment of the
middle cerebral artery; M2-M4, second to fourth segment of the middle cerebral artery; NIHSS, National Institutes of Health stroke scale; tPA, tissue plasminogen activator (Alteplase);
TVL, target vessel location.

FIGURE 3

Relationship between functional independence rates (90 day mRS 0–2) and onset-to-puncture time for direct (solid, blue) vs. transfer (dashed,
red) patients. Onset-to-puncture times >1.5 times the interquartile range are not displayed. Shaded areas for each group represent 95%
conﬁdence intervals. mRS, modiﬁed Rankin Scale; p = 0.6612 for interaction.

<20 miles to an endovascular-capable center, tPA is delayed
by only 6.9 min, while endovascular treatment to begin 94 min
sooner (7).

patients to a nearer hospital, direct-to-endovascular bypass
may still be beneficial because it accelerates the start of
endovascular therapy. For example, when modeling a bypass
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Nevertheless, the use of bridging thrombolysis when
appropriate may alleviate the difference in transport paradigms,
potentially by compensating for the negative effects of delayed
reperfusion time: Zhao et al. (16) found in a subgroup analysis
of that bridging thrombolysis resulted in similar outcomes
for direct and transfer cohorts with respect to sICH, 90-day
favorable functional outcome, 90-day mortality, and successful
recanalization. In practice, however, the authors concur that for
patients ineligible for IV thrombolysis, direct transport to the
closest endovascular-capable center may be the best option (16).
Our results establish that AIS-LVO patients treated with
frontline aspiration thrombectomy can also benefit significantly
from direct routing to endovascular-capable centers. Further
work should focus on in-field patient screening tools and
controlled trials, e.g., RACECAT (NCT02795962), to provide
crucial data to inform pre-hospital management systems for
AIS-LVO. In the RACECAT trial, no differences were found
between direct vs. transfer patient cohorts in Catalonia admitted
for thrombectomy within 7 h of symptom onset (8). While
RACECAT provides important data on the efficiency of
stroke care in Catalonia, outcomes from the region’s single,
integrated, public-use healthcare network (which covers the
entire Catalonian population of 7.5 million) (21) might not
be generalizable to health systems elsewhere in the world, and
raises vital questions regarding whether aspects of this system
can be adapted to other urban and rural catchments. For
instance, the onset-to-puncture times in RACECAT were only
delayed by 56 min for transfer patients (onset-to-puncture for
transfer was 270 vs. 214 min for direct) (8). By comparison,
in our registry, onset-to-puncture time delay was 148 min
(339 min for transfer vs. 191 min for direct, p < 0.0001)
– nearly triple that of RACECAT. This much longer delay
in onset-to-puncture time encountered in our registry may
explain why in RACECAT, direct and transfer had equivalent
outcomes, but in our registry, direct admission patients had
significantly higher rates of good functional outcome (mRS 0–
2) at 90 days. This point is supported by our multivariable
logistic regression (Table 4) which found longer onset-topuncture (per 30 min increase) to be a significant independent
predictor of worse functional outcome at 90 days [OR 0.85
(95% CI 0.74, 0.97), p = 0.0180], whereas direct admission
was not found to be a significant independent predictor
[OR 2.17 (95% CI 0.42, 11.3), p = 0.3584].
An important consideration in design of COMPLETE
compared to studies such as RACECAT, STRATIS, and
DEFUSE-3, is that COMPLETE was a highly inclusive, realworld evaluation of global AIS-LVO treatment. COMPLETE
was a global registry that included patients for aspiration
thrombectomy with no restrictions on stroke location
(anterior/posterior) or onset time. COMPLETE provides
real-world data on outcomes based on local systems of care,
transfer patterns, and time delays across broad geographies.
This experience showed that under current systems of care,
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direct admission is appropriate for a majority of admitted
strokes. However, each locality should develop their own stroke
protocols based on the location of, and transit time required
to reach a comprehensive stroke center or a stroke center with
thrombectomy capability.
Additional research should focus on AIS-LVO detection
to facilitate direct routing of patients to appropriate treatment
centers. We concur with the need for well-designed,
randomized-controlled trials to evaluate AIS-LVO systems
of care based on regional access characteristics and patient
populations (20, 22).

Limitations
A limitation of this non-randomized study is the lack
of a comparator arm. This study also did not track the
decision making process for determining if a patient should be
transferred or directly admitted, the distance from location of
symptom onset to thrombectomy center (hub), any time metrics
related to the initial institution (spoke) for transfer patients
(e.g., onset to spoke arrival time, spoke door in to door out
time, spoke departure to hub arrival time), nor time of IV-tPA
administration, thus limiting possible analyses. Additionally, the
conclusions of this analysis may not be widely applicable where
primary and comprehensive stroke centers are not similarly
accessible for all patients and direct admission may not be an
option for many geographical areas.
Nevertheless, this large, prospective registry was core-lab
adjudicated, and safety results were assessed by independent
medical reviewers. This registry also enrolled patients from a
large, heterogeneous population that included posterior lesions,
and did not exclude patients based on presentation window.

Conclusion
In the COMPLETE registry, patients directly admitted
to an endovascular-capable center for frontline aspiration
thrombectomy experienced significantly faster onset-topuncture times and better rates of good functional outcome
at 90 days.
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